Multiple Myeloma Treatment Options: What to Expect at Each Stage

Daratumumab. Lenalidomide. Bortezomib. A new diagnosis often arrives with a vocabulary lesson nobody asked for, like being handed a menu in a language you don’t speak.

Multiple myeloma treatment becomes easier to follow once you understand why several drugs are used together, where a transplant fits, and how the plan changes if the disease returns. And with more options than there were even a few years ago, your team often has another approach to consider if one stops working.

How Multiple Myeloma Treatment Works

If you’re still piecing together what’s been happening in your body, our guide to multiple myeloma symptoms is the place to start.

Myeloma treatment is a relay, not a sprint. The goal is to push the disease into deep remission, hold it there as long as possible, and, when it eventually returns, switch to different tools. Doctors call a planned course of treatment a line of therapy: the starting drugs, a transplant, and maintenance can all belong to the same first line. If the disease returns or stops responding, your team moves to another line, which is the usual course, not a sign that something went wrong.

The first fork in the road is whether you’re a candidate for a stem cell transplant. That depends far more on overall fitness than on age, so a vigorous 70-year-old may qualify while a frailer 60-year-old may not.

First-Line Treatment Options

For many people who are fit enough for it, treatment now starts with a four-drug combination, and each drug attacks myeloma in a different way:^[1]

• An anti-CD38 antibody (daratumumab or isatuximab) tags myeloma cells so your immune system can find them.
• Bortezomib, a proteasome inhibitor, jams the cell’s waste-disposal system. Myeloma cells are protein factories, so they choke on the backlog faster than healthy cells do.
• Lenalidomide, an immunomodulatory drug, shuts down proteins myeloma cells depend on and wakes up nearby immune cells.
• Dexamethasone, a steroid, kills myeloma cells directly and calms inflammation.

Many doses are given as injections or taken at home, but the early months can still involve frequent clinic visits. Lenalidomide is a capsule, and dexamethasone is a weekly pill that can bring insomnia and mood swings. This starting phase often runs four to six months, depending on the regimen. If you’re older or frail, your team may use a lighter version with fewer drugs or lower doses. The aim is a treatment you can tolerate well enough to keep benefiting from.

Expect regular blood tests, too: M protein and free light chain levels show how well treatment is working, and doses or schedules may change if side effects build up.

Stem Cell Transplant for Myeloma

For people who qualify, the next step is an autologous stem cell transplant, meaning the cells are your own. They’re collected from your blood and frozen. High-dose chemotherapy (melphalan) then kills myeloma cells but also damages healthy blood-forming cells, and the returned stem cells help restore blood production.

A transplant isn’t a cure, but it deepens and lengthens remission.^[2] The price is a rough few weeks of low blood counts, mouth sores, nausea, and infection risk, with fatigue that can linger for months.

Some people collect and freeze their stem cells early but delay the transplant. Whether that makes sense depends on disease risk, treatment response, and personal priorities, so it’s worth a frank conversation with your team.

Maintenance Therapy for Myeloma

Maintenance looks a little different depending on your path. After a transplant, it usually means lenalidomide, alone or paired with an anti-CD38 antibody, often continued for years. Without a transplant, some drugs are reduced or stopped while others continue, often an antibody with lenalidomide and sometimes dexamethasone. Either way, the aim is to keep any remaining myeloma cells asleep.

It’s a quieter phase, not a side-effect-free one. Low blood counts, diarrhea, and fatigue are the usual concerns, and long-term lenalidomide carries a small added risk of other cancers that your team will monitor.

Many centers now track MRD (measurable residual disease), usually on a bone marrow sample, with a test sensitive enough to find one myeloma cell among 100,000 or more healthy ones. Repeated results can help your team discuss whether maintenance should change, but one negative MRD test doesn’t automatically mean maintenance can stop.^[3]

Treatment for Relapsed Myeloma

When myeloma does return, you’re not starting over. Your team chooses the next move based on what you’ve already had, which drugs the myeloma has stopped responding to, how long the last remission lasted, and your general health. Switching to a different drug within the familiar families is common, and three newer approaches have widened the options.

CAR-T Cell Therapy

Your own T cells are collected, engineered in a lab to hunt a protein called BCMA on myeloma cells, and infused back after a short course of chemotherapy. It’s essentially a one-time treatment that can produce long remissions. The catches: manufacturing takes weeks, you’ll usually need to stay near the treatment center for at least two weeks afterward, and it can cause cytokine release syndrome (fever, low blood pressure) and neurological complications, some of which can be serious or last longer. In the US, one CAR-T product can be used as early as the first relapse for certain people.^[4]

Bispecific Antibodies

These are off-the-shelf drugs with two arms: one grabs a T cell, the other grabs a myeloma cell, pulling them together. Teclistamab, elranatamab, and linvoseltamab target BCMA, while talquetamab targets a protein called GPRC5D and often causes skin, nail, and taste changes. They’re no longer limited to people who have tried many earlier treatments; in the US, teclistamab, for instance, can be paired with daratumumab from the first relapse.^[5] Depending on the drug, treatment is given by injection or IV infusion, on a schedule that can stretch from weekly to monthly. Small starting doses and close monitoring help manage early reactions, such as cytokine release syndrome. The main longer-term risk is infection, so prevention is built into the plan.

Choosing between CAR-T and a bispecific is partly about logistics: CAR-T asks for a big upfront effort and then offers the possibility of time without ongoing anti-myeloma treatment, while bispecifics start sooner and are typically continued. Neither is universally better, so the right pick depends on your disease, your health, and how close you live to a specialist center.

Iberdomide and CELMoD Therapy

In the US, iberdomide, a capsule, recently received accelerated approval as the first of a drug class called CELMoDs, for use alongside daratumumab and dexamethasone after earlier treatment.^[6] Doctors are still refining where it fits best.

Supportive Care During Treatment

Good myeloma care also means keeping you safe while treatment works:

• Bones: zoledronic acid infusions or denosumab injections help prevent fractures.^[7] Denosumab is typically given every four weeks; zoledronic acid is often monthly at first, sometimes spaced out later. Get a dental check first, because these drugs can occasionally affect the jaw.
• Infections: most people take an antiviral to prevent shingles, and some receive immunoglobulin infusions when antibody levels run low. Vaccines are best planned with your team: ideally before treatment starts, and usually repeated after a transplant. Live vaccines are generally avoided. A fever of 100.4°F (38°C) or higher means calling your treatment team immediately.
• Blood clots: when lenalidomide is in the plan, a daily aspirin or a blood thinner is often added.
• Nerves: bortezomib can cause tingling in the fingers and toes. Reporting it early lets your doctor adjust the dose before it gets harder to reverse.
• Radiation: a short course can ease pain from a specific bone.

Choosing Your Treatment Plan

Clinical trials deserve a place in the conversation from the start, not just as a last resort. Many of the drugs above were once trial-only, and a trial can offer access to a promising treatment that isn’t widely available yet. It’s also reasonable to bring a myeloma specialist in early, even if your day-to-day care stays closer to home.

Before you agree to any plan, ask three things: What is the goal of this treatment? Which side effects should prompt an immediate call? And what is the next step if this stops working?

Which of these drugs you can get depends on where you live and what your health system covers, so treat the names here as a map, not a prescription. The logic travels everywhere: start strong, protect yourself, and understand what could come next. The options keep expanding, which is worth holding onto. Your job isn’t to master every drug name. It’s to stay in the conversation and ask for the plan in plain language.